[go: up one dir, main page]

IL160148A0 - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor - Google Patents

Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor

Info

Publication number
IL160148A0
IL160148A0 IL16014802A IL16014802A IL160148A0 IL 160148 A0 IL160148 A0 IL 160148A0 IL 16014802 A IL16014802 A IL 16014802A IL 16014802 A IL16014802 A IL 16014802A IL 160148 A0 IL160148 A0 IL 160148A0
Authority
IL
Israel
Prior art keywords
metastasis
recurrence
inhibiting
preventing
pharmaceutical compositions
Prior art date
Application number
IL16014802A
Other languages
English (en)
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of IL160148A0 publication Critical patent/IL160148A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL16014802A 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor IL160148A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001249717 2001-08-21
PCT/JP2002/008309 WO2003015826A1 (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor

Publications (1)

Publication Number Publication Date
IL160148A0 true IL160148A0 (en) 2004-07-25

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16014802A IL160148A0 (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor

Country Status (18)

Country Link
EP (1) EP1418947A1 (zh)
KR (1) KR20040027972A (zh)
CN (1) CN100372570C (zh)
AR (1) AR035137A1 (zh)
AU (1) AU2002328093B2 (zh)
BR (1) BR0212036A (zh)
CA (1) CA2457056C (zh)
HU (1) HUP0401351A3 (zh)
IL (1) IL160148A0 (zh)
MX (1) MXPA04001599A (zh)
NO (1) NO20041194L (zh)
NZ (1) NZ530947A (zh)
PL (1) PL368319A1 (zh)
RU (1) RU2275913C2 (zh)
TW (1) TWI313609B (zh)
UA (1) UA75450C2 (zh)
WO (1) WO2003015826A1 (zh)
ZA (1) ZA200400917B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
EP2313487B1 (en) 2008-07-16 2018-04-04 Children's Medical Center Corporation Organ mimic device with microchannels and methods of use
WO2012166903A1 (en) * 2011-06-02 2012-12-06 President And Fellows Of Harvard College Methods and uses for ex vivo tissue culture systems
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
BR122021014396B1 (pt) * 2012-10-11 2022-07-05 Daiichi Sankyo Company, Limited Compostos intermediários ligantes de fármacos, e ligante
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
BR112016013482B1 (pt) 2014-01-31 2022-04-19 Daiichi Sankyo Company, Limited Conjugado de anticorpo anti-her2-fármaco, fármacos antitumor e/ou anticâncer e composição farmacêutica
JP6948951B2 (ja) 2015-05-04 2021-10-13 ファイザー・インク Ｂ群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
IL290959B2 (en) 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Preparations containing antibody-drug conjugates and methods for their production
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
CN112351999A (zh) 2018-05-18 2021-02-09 第一三共株式会社 抗-muc1抗体-药物缀合物
TWI822822B (zh) 2018-07-31 2023-11-21 日商第一三共股份有限公司 抗體-藥物結合物之用途
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195324T1 (de) * 1993-02-26 2000-08-15 Drug Delivery System Inst Ltd Polysaccharidderivat und wirkstoffträger
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
JP4420472B2 (ja) * 1996-04-15 2010-02-24 旭化成株式会社 薬物複合体
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (zh) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 低收缩性光固化涂层材料及其制法和用途
CA2333321A1 (en) * 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Drug complex

Also Published As

Publication number Publication date
RU2004108141A (ru) 2005-04-20
PL368319A1 (en) 2005-03-21
NZ530947A (en) 2006-04-28
HUP0401351A2 (hu) 2004-12-28
CA2457056A1 (en) 2003-02-27
NO20041194L (no) 2004-03-19
AU2002328093B2 (en) 2005-05-05
HUP0401351A3 (en) 2011-02-28
KR20040027972A (ko) 2004-04-01
UA75450C2 (en) 2006-04-17
CA2457056C (en) 2008-07-22
BR0212036A (pt) 2004-08-17
CN100372570C (zh) 2008-03-05
WO2003015826A1 (en) 2003-02-27
TWI313609B (en) 2009-08-21
CN1545423A (zh) 2004-11-10
EP1418947A1 (en) 2004-05-19
RU2275913C2 (ru) 2006-05-10
ZA200400917B (en) 2004-08-25
MXPA04001599A (es) 2004-07-08
AR035137A1 (es) 2004-04-14

Similar Documents

Publication Publication Date Title
IL160148A0 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor
AU3983201A (en) Compositions and methods for the early diagnosis of ovarian cancer
HK1131165A1 (zh) 幫助調控血管生成、抑制轉移和腫瘤纖維化以及評估結腸癌腫瘤的惡性程度的藥物組合物及方法
IL152315A0 (en) Soluble ctla4 mutant molecules and pharmaceutical compositions containing the same
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
PL354540A1 (en) Drugs for the treatment of malignant tumours
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
AU9684601A (en) Compositions that inhibit proliferation of cancer cells
EP1461033A4 (en) METHOD AND COMPOSITIONS FOR REDUCING UNWANTED EFFECTS OF CHEMOTHERAPY
AU2002257033A1 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA
GB0110847D0 (en) Breast cancer detection
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
HUP0300772A3 (en) Medicament for the immunotherapy of malignant tumours
HUP0302629A3 (en) Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002332606A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
GB2379444A9 (en) Assay for cancer of the prostate
AU5802200A (en) Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors
IL129154A0 (en) Pharmaceutical preparation useful for the prevention of cancer metastasis
WO2003020115A9 (en) Methods and compositions for the detection of cancer